Shafie A, Ashour A, Anwar S, Anjum F, Hassan M
Arch Pharm Res. 2024; 47(6):571-595.
PMID: 38764004
DOI: 10.1007/s12272-024-01499-w.
Chen Y, Sun J, Tao J, Sun T
Front Neurosci. 2024; 17:1322486.
PMID: 38249579
PMC: 10796816.
DOI: 10.3389/fnins.2023.1322486.
Wiprich M, da Rosa Vasques R, Gusso D, Rubensam G, Kist L, Bogo M
Mol Neurobiol. 2023; 61(2):609-621.
PMID: 37648841
DOI: 10.1007/s12035-023-03584-5.
Jiang A, Handley R, Lehnert K, Snell R
Int J Mol Sci. 2023; 24(16).
PMID: 37629202
PMC: 10455900.
DOI: 10.3390/ijms241613021.
Placido E, Gomes Welter P, Wink A, Karasiak G, Outeiro T, Dafre A
Int J Mol Sci. 2023; 24(16).
PMID: 37628801
PMC: 10454852.
DOI: 10.3390/ijms241612607.
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.
Wong T, Li G, Li S, Gao W, Chen G, Gan S
Signal Transduct Target Ther. 2023; 8(1):177.
PMID: 37137892
PMC: 10154768.
DOI: 10.1038/s41392-023-01427-2.
More than Addiction-The Nucleus Accumbens Contribution to Development of Mental Disorders and Neurodegenerative Diseases.
Bayassi-Jakowicka M, Lietzau G, Czuba E, Patrone C, Kowianski P
Int J Mol Sci. 2022; 23(5).
PMID: 35269761
PMC: 8910774.
DOI: 10.3390/ijms23052618.
New Avenues for the Treatment of Huntington's Disease.
Kim A, Lalonde K, Truesdell A, Gomes Welter P, Brocardo P, Rosenstock T
Int J Mol Sci. 2021; 22(16).
PMID: 34445070
PMC: 8394361.
DOI: 10.3390/ijms22168363.
Purinergic Signaling in the Pathophysiology and Treatment of Huntington's Disease.
Wiprich M, Bonan C
Front Neurosci. 2021; 15:657338.
PMID: 34276284
PMC: 8281137.
DOI: 10.3389/fnins.2021.657338.
Investigating the Transition of Pre-Symptomatic to Symptomatic Huntington's Disease Status Based on Omics Data.
Christodoulou C, Zachariou M, Tomazou M, Karatzas E, Demetriou C, Zamba-Papanicolaou E
Int J Mol Sci. 2020; 21(19).
PMID: 33049985
PMC: 7582902.
DOI: 10.3390/ijms21197414.
Progression of basal ganglia pathology in heterozygous Q175 knock-in Huntington's disease mice.
Deng Y, Wang H, Joni M, Sekhri R, Reiner A
J Comp Neurol. 2020; 529(7):1327-1371.
PMID: 32869871
PMC: 8049038.
DOI: 10.1002/cne.25023.
The Renin-Angiotensin System in Huntington's Disease: Villain or Hero?.
Machado T, Guatimosim C, Kangussu L
Protein Pept Lett. 2020; 27(6):456-462.
PMID: 31933441
PMC: 7403685.
DOI: 10.2174/0929866527666200110154523.
Huntington's disease: the coming of age.
Pandey M, Rajamma U
J Genet. 2018; 97(3):649-664.
PMID: 30027901
Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington's disease.
Covey D, Dantrassy H, Yohn S, Castro A, Conn P, Mateo Y
Neuropsychopharmacology. 2018; 43(10):2056-2063.
PMID: 29925886
PMC: 6098121.
DOI: 10.1038/s41386-018-0107-8.
Disrupted striatal neuron inputs and outputs in Huntington's disease.
Reiner A, Deng Y
CNS Neurosci Ther. 2018; 24(4):250-280.
PMID: 29582587
PMC: 5875736.
DOI: 10.1111/cns.12844.
Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review.
Jamwal S, Kumar P
Curr Neuropharmacol. 2018; 17(2):165-175.
PMID: 29512464
PMC: 6343208.
DOI: 10.2174/1570159X16666180302115032.
Disease-modifying effects of ganglioside GM1 in Huntington's disease models.
Alpaugh M, Galleguillos D, Forero J, Morales L, Lackey S, Kar P
EMBO Mol Med. 2017; 9(11):1537-1557.
PMID: 28993428
PMC: 5666311.
DOI: 10.15252/emmm.201707763.
Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine Modulation.
Rangel-Barajas C, Rebec G
J Huntingtons Dis. 2016; 5(4):303-331.
PMID: 27983564
PMC: 5181679.
DOI: 10.3233/JHD-160221.
Corticostriatal Dysfunction in Huntington's Disease: The Basics.
Bunner K, Rebec G
Front Hum Neurosci. 2016; 10:317.
PMID: 27445757
PMC: 4924423.
DOI: 10.3389/fnhum.2016.00317.
Components of the endocannabinoid and dopamine systems are dysregulated in Huntington's disease: analysis of publicly available microarray datasets.
Laprairie R, Bagher A, Precious S, Denovan-Wright E
Pharmacol Res Perspect. 2015; 3(1):e00104.
PMID: 25692022
PMC: 4317235.
DOI: 10.1002/prp2.104.